ReviewJournal of the Endocrine Society2025
Exploring the Role of the Gut Microbiome Across the Lifespan: Implications for Aging and Metabolic Disorders.
Review in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Obesity accelerates aging: Mechanisms and therapeutic implications.Genes & diseases · 2026Review
- The Inflammaging-Redox-InflammamiR Axis in Metabolic Aging: From Diagnostic Clusters to Integrated Risk Phenotypes.Biomolecules · 2026Review
- Age and sex dependent shift in murine gut microbiome reveals pathological links to host cardiovascular and metabolic pathways.GeroScience · 2026Article
- Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia.Journal of obesity & metabolic syndrome · 2026Review
- Gut microbiota-derived metabolites as immune modulators in aging and age-related chronic inflammatory diseases.Ageing research reviews · 2026Review
- Molecular Mechanisms of the Microbiota-Gut-Brain Axis in the Onset and Progression of Stroke.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiome is widely accepted to play a crucial role in human health and disease. These intestinal microbiota are not only involved in gastrointestinal physiology, but they also contribute to essential immune modulation and metabolic homeostasis. Growing evidence suggests that alterations in the gut microbiota composition are linked to various metabolic disorders, including obesity and age-related diseases. Obesity, a global public health concern, is associated with shifts in microbial diversity and functionality, which influence energy extraction, fat storage, and systemic inflammation. Similarly, age-related disorders, such as neurodegenerative diseases, sarcopenia, and metabolic syndromes are linked to gut microbiome alterations that exacerbate chronic inflammation and metabolic dysfunction. Understanding the intricate relationship between the gut microbiome, obesity, and aging-related pathologies is essential for developing targeted microbiome-based interventions to mitigate these health challenges. In this review, after a brief summary of the development of the gut microbiome across the lifespan and its modulating factors, we will focus on the mechanisms underlying the relation between the gut microbiome and metabolic and aging-related disorders. Finally, the findings of interventional studies underscoring causality and the potential future directions will be discussed, with a focus on the possibility of modifying the progression of metabolic and age-related diseases through the modulation of the gut microbiome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.